midazolam has been researched along with Psoriasis in 5 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The PKs of midazolam, metabolized by CYP3A4, was evaluated before and after 7 and 35 days of treatment initiation of subcutaneous secukinumab at a dose of 300 mg weekly in 24 patients with moderate-to-severe psoriasis." | 7.91 | Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. ( Boutouyrie-Dumont, B; Bruin, G; Calonder, C; Hasselberg, A; Koroleva, I; Milojevic, J; Pariser, DM; Soon, R; Woessner, R, 2019) |
| "Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98." | 5.30 | Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. ( Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y, 2019) |
| " The PKs of midazolam, metabolized by CYP3A4, was evaluated before and after 7 and 35 days of treatment initiation of subcutaneous secukinumab at a dose of 300 mg weekly in 24 patients with moderate-to-severe psoriasis." | 3.91 | Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. ( Boutouyrie-Dumont, B; Bruin, G; Calonder, C; Hasselberg, A; Koroleva, I; Milojevic, J; Pariser, DM; Soon, R; Woessner, R, 2019) |
| " The probe cocktail was generally well-tolerated when administered in combination with guselkumab in patients with psoriasis." | 2.94 | Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. ( Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y, 2020) |
| " Apparent oral clearance and relative bioavailability for caffeine and S-warfarin were not significantly different between the subject populations." | 2.72 | Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates. ( Mohamed, MF; Othman, AA; Sathe, AG, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Xu, Y | 1 |
| Zhuang, Y | 1 |
| Piantone, A | 1 |
| Shu, C | 1 |
| Chen, D | 1 |
| Zhou, H | 1 |
| Xu, Z | 1 |
| Sharma, A | 1 |
| Sathe, AG | 1 |
| Othman, AA | 2 |
| Mohamed, MF | 1 |
| Khalilieh, S | 1 |
| Hussain, A | 1 |
| Montgomery, D | 1 |
| Levine, V | 1 |
| Shaw, PM | 1 |
| Bodrug, I | 1 |
| Mekokishvili, L | 1 |
| Bailey-Smith, C | 1 |
| Glasgow, XS | 1 |
| Cheng, A | 1 |
| Martinho, M | 1 |
| Iwamoto, M | 1 |
| Khatri, A | 1 |
| Cheng, L | 1 |
| Camez, A | 1 |
| Ignatenko, S | 1 |
| Pang, Y | 1 |
| Bruin, G | 1 |
| Hasselberg, A | 1 |
| Koroleva, I | 1 |
| Milojevic, J | 1 |
| Calonder, C | 1 |
| Soon, R | 1 |
| Woessner, R | 1 |
| Pariser, DM | 1 |
| Boutouyrie-Dumont, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis[NCT02397382] | Phase 1 | 16 participants (Actual) | Interventional | 2015-06-18 | Completed | ||
| The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients Wit[NCT02772601] | Phase 1 | 21 participants (Actual) | Interventional | 2016-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for midazolam and Psoriasis
| Article | Year |
|---|---|
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Topics: Adult; Biological Availability; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Cytochrome | 2021 |
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Topics: Adult; Biological Availability; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Cytochrome | 2021 |
3 trials available for midazolam and Psoriasis
| Article | Year |
|---|---|
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P | 2020 |
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P | 2020 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cy | 2018 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cy | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; | 2019 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; | 2019 |
1 other study available for midazolam and Psoriasis
| Article | Year |
|---|---|
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Cytochrome P-450 CYP3A; Drug Interaction | 2019 |
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Cytochrome P-450 CYP3A; Drug Interaction | 2019 |